DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Elizabeth Smelov - 6 WSJ’s Dion Rabouin - 4 WSJ’s Daniela Hernandez - 4 WSJ’s Dalvin Brown - 2 Eli Lilly ’ - 1 Ozempic - 1 Elizabeth Smelov Eli Lilly ’ - 1 Mounjaro - 1
Top related locs:
China Beijing Elizabeth Smelov U.S Novo Denmark’s Novo Danish Denmark semiautonomous
Top related orgs:
Novo Nordisk - 2 Apple - 2 SINGAPORE - 1 Drug Administration - 1 Denmark’s - 1 Denmark’s Novo Nordisk - 1 Huawei Technologies - 1 Foxconn - 1

Search resuls for: "Elizabeth Smelov"


25 mentions found


☆ China’s Economy Faces a Sour End to the Year
  + stars: | 2023-11-30 | by ( Jason Douglas | ) www.wsj.com   time to read: 1 min
China’s slowing economy could soon become a major talking point for U.S. companies as they begin to report third-quarter earnings. WSJ’s Dion Rabouin explains. Illustration: Elizabeth Smelov<br>SINGAPORE—A brief rebound in China’s struggling economy showed worrying new signs of flickering out, heaping pressure on Beijing to take bolder steps to rev up growth. Factory activity slid deeper into contraction in November as domestic and foreign orders dried up, while, in an ominous sign for consumer spending, activity in the services sector shrank for the first time this year, according to business surveys released Thursday. Only construction registered any expansion compared with the previous month as government spending on infrastructure increased.
Persons: WSJ’s Dion Rabouin, Elizabeth Smelov Organizations: SINGAPORE Locations: Beijing
☆ Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
  + stars: | 2023-11-08 | by ( Peter Loftus | ) www.wsj.com   time to read: 1 min
Earlier: Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovU.S. drug regulators have approved expanding the use of Eli Lilly ’s diabetes drug Mounjaro to include the treatment of obesity. The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk —that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov, Eli Lilly ’, Ozempic Organizations: Novo Nordisk Locations: Elizabeth Smelov U.S, Novo
☆ Obesity Drug Demand Outstrips Supply
  + stars: | 2023-11-02 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovEli Lilly ’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk , which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Eli Lilly ’, Mounjaro, Lilly Organizations: Drug Administration, Denmark’s, Denmark’s Novo Nordisk Locations: Denmark’s Novo
☆ Apple Sales Decline as China Market Weighs on Earnings Report
  + stars: | 2023-11-02 | by ( Aaron Tilley | ) www.wsj.com   time to read: 1 min
China’s slowing economy could soon become a major talking point for U.S. companies as they begin to report third-quarter earnings. WSJ’s Dion Rabouin explains. Illustration: Elizabeth SmelovApple said sales fell for the fourth consecutive quarter, including a decline in China that came as the company faces a broad economic slowdown in the country and new competition from rival Huawei Technologies. The September quarter marks the fourth straight period in which Apple reported year-over-year declines in total revenue, the longest such slump in years. Apple sales were $89.5 billion, down less than 1% from the previous year and largely in line with analyst estimates, even as net income of about $23 billion exceeded expectations.
Persons: WSJ’s Dion Rabouin, Elizabeth Smelov Apple Organizations: Huawei Technologies, Apple Locations: China
☆ Wegovy Maker Novo Nordisk’s Profit Surges on Weight-Loss-Drug Demand
  + stars: | 2023-11-02 | by ( Dominic Chopping | ) www.wsj.com   time to read: 1 min
Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovWegovy maker Novo Nordisk reported soaring profit, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe’s most valuable company. Surging demand for the drugs has supercharged the company’s stock price, tilted the scales of its home economy in Denmark and triggered a frenzy on Wall Street over how the treatments and others like it might affect other industries, including snack foods and airlines.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Organizations: Novo Nordisk Locations: Danish, Denmark
☆ For China, Bullying Apple Suppliers Could Backfire Badly
  + stars: | 2023-10-30 | by ( Jacky Wong | Nathaniel Taplin | ) www.wsj.com   time to read: 1 min
China’s slowing economy could soon become a major talking point for U.S. companies as they begin to report third-quarter earnings. Illustration: Elizabeth SmelovChina’s surprise investigation into Apple supplier Foxconn, a key link in the iPhone supply chain, may be intended to send a message. The one Apple and its suppliers actually receive might do China more harm than good. Chinese authorities have launched tax and land-use probes into subsidiaries of Foxconn , formally known as Hon Hai Precision Industry , the company confirmed last week. That is surprising since Foxconn, which is the world’s largest contract electronics manufacturer, has long had an amicable relationship with China—and is one of the biggest employers in the country.
Persons: WSJ’s Dion Rabouin, Elizabeth Smelov China’s Organizations: Apple, Foxconn, Hai Precision Industry Locations: China
☆ Hong Kong’s Financial-Sector Feast Turns to Famine
  + stars: | 2023-10-20 | by ( Jacky Wong | ) www.wsj.com   time to read: 1 min
China’s slowing economy could soon become a major talking point for U.S. companies as they begin to report third-quarter earnings. WSJ’s Dion Rabouin explains. Illustration: Elizabeth SmelovHong Kong’s lackluster stock market epitomizes the challenges that the city is grappling with—China’s economic slowdown, which looks increasingly structural, and Beijing’s tightened grip on the semiautonomous city. Neither issue looks likely to disappear soon, although China’s economy could improve a bit cyclically next year. Weak third-quarter results released Friday by Hong Kong Exchanges and Clearing —the market’s owner and operator—are the latest sign of how entrenched the city’s problems have become.
Persons: WSJ’s Dion Rabouin, Elizabeth Smelov Hong Organizations: Hong Kong Exchanges Locations: semiautonomous
☆ Ozempic Boom Is an Opportunity for Health Insurers
  + stars: | 2023-10-20 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
WSJ’s Daniela Hernandez breaks down the science of how diabetes drugs work—and how they could change psychiatry. Photo illustration: Elizabeth SmelovYou would think a new class of high-price weight loss drugs taken by millions of Americans would be a problem for health insurers. But it is more complicated than that: Some insurance giants actually stand to profit from the Ozempic craze. The industry has been calling out the costs of GLP-1 drugs, which are used for both diabetes and obesity. But federally supported Medicare and Medicaid still don’t cover the drugs for obesity, and much of the commercial market is self-insured.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov, Aetna
☆ Watch: Sen. Mitt Romney Announces He Won’t Seek Re-Election
  + stars: | 2023-09-13 | by ( ) www.wsj.com   time to read: 1 min
Apple's Switch to USB-C: iPhone Users Will Learn Not All Cords Are EqualApple’s new iPhones will all have a USB-C port. Goodbye Lightning. But with so many different USB-C cables around, which one is right for you? WSJ’s Dalvin Brown unpacks the switch and which cables could work for you. Photo: Elizabeth Smelov
Persons: WSJ’s Dalvin Brown, Elizabeth Smelov
☆ Watch: Escaped Pennsylvania Inmate Danelo Cavalcante Is Captured
  + stars: | 2023-09-13 | by ( ) www.wsj.com   time to read: 1 min
Apple's Switch to USB-C: iPhone Users Will Learn Not All Cords Are EqualApple’s new iPhones will all have a USB-C port. Goodbye Lightning. But with so many different USB-C cables around, which one is right for you? WSJ’s Dalvin Brown unpacks the switch and which cables could work for you. Photo: Elizabeth Smelov
Persons: WSJ’s Dalvin Brown, Elizabeth Smelov
☆ Obesity Could Be Pharma’s Biggest Blockbuster Yet
  + stars: | 2023-05-05 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovAs social-media hype around drugs like Ozempic and Mounjaro explodes, patient testimonies have focused not only on the dramatic effect on their waistlines, but also on how quickly many seem to pack the pounds back on if they stop taking the injections. That may not be ideal for patients, but for Wall Street it is a feature rather than a bug. Nothing gets investors more hyped up than a product whose target market is massive—more than 40% of American adults are obese—and that also needs to be taken indefinitely.
☆ Why You Might Not Be Able to Start Taking Wegovy
  + stars: | 2023-05-04 | by ( Dominic Chopping | Peter Loftus | ) www.wsj.com   time to read: 1 min
Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovThe Danish pharmaceutical giant that makes the obesity drug Wegovy said it would temporarily hold back some lower-strength starter doses in the U.S. in an effort to safeguard supplies for current patients amid soaring demand. The Food and Drug Administration cleared Wegovy, made by Novo Nordisk , as a treatment for chronic weight management in 2021. It has since exploded in popularity.
☆ Obesity Drug Hype Outweighs Profit Miss at Eli Lilly
  + stars: | 2023-04-27 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
Illustration: Elizabeth SmelovEli Lilly first-quarter profit miss will hardly matter for investors, who got plenty of good news on the company’s most important drug. The company announced results from a late stage study on Thursday showing that Mounjaro helped people with Type 2 diabetes who are also overweight or obese lose up to 15.7% of their body weight. The results arguably bested a similar study by Novo Nordisk , which showed that its competitor drug Wegovy led to an average weight loss of 9.6%.
☆ Mounjaro Helps Diabetes Patients Lose ‘Meaningful’ Weight, Study Shows
  + stars: | 2023-04-27 | by ( Peter Loftus | ) www.wsj.com   time to read: 1 min
Illustration: Elizabeth SmelovEli Lilly & Co.’s drug Mounjaro for Type 2 diabetes helped people who are also overweight or obese lose up to 15.7% of their body weight, in a new study that could pave the way for Lilly to promote the drug as a weight-loss treatment. Indianapolis-based Lilly said that with the new data, it will complete in the coming weeks an application to the U.S. Food and Drug Administration to market Mounjaro as an anti-obesity treatment, which could enable an FDA decision by the end of the year.
☆ Weight-Loss Drugmakers Lobby for Medicare Coverage
  + stars: | 2023-04-24 | by ( Liz Essley Whyte | ) www.wsj.com   time to read: 1 min
Illustration: Elizabeth SmelovWeight-loss drugmakers are lobbying Congress to grant them access to a monster payday for their blockbuster treatments: Medicare coverage. New drugs to treat diabetes and obesity are helping people shed pounds and generating huge sales for Novo Nordisk AS and Eli Lilly & Co. But they cost hundreds of dollars a month or more and Medicare doesn’t cover them to treat obesity. The law governing Medicare’s prescription-drug benefit excludes weight drugs. If that changed, demand from the 65 million older and disabled people insured through Medicare could push sales even higher.
☆ AirPods Are Unrepairable. Here’s Why.
  + stars: | 2023-04-21 | by ( Dalvin Brown | ) www.wsj.com   time to read: 1 min
E28How Smartphone Cases Are Ready for New iPhones Even Before They Release As soon as Apple releases new products, third-party cases and compatible accessories seem to instantly hit the shelves. How is this possible when cases can take months to design and mass produce? WSJ’s Dalvin Brown explains. Illustration: Elizabeth Smelov
☆ What Is Ozempic and Why Is It Such a Big Deal Right Now?
  + stars: | 2023-04-20 | by ( Peter Loftus | ) www.wsj.com   time to read: 1 min
Illustration: Elizabeth SmelovA drug approved by the Food and Drug Administration to treat people with Type 2 diabetes has ignited a craze among social-media influencers, the rich and famous and everyday people alike. Ozempic, made by Novo Nordisk A/S, has gained popularity for its off-label use, helping users drop excess pounds within a matter of months. Demand has soared for Ozempic as well its sister drug, Wegovy, and Eli Lilly & Co.’s Mounjaro. Ozempic’s main ingredient, known as semaglutide, is in Wegovy, which was approved by the FDA in 2021 to treat obesity. Lilly’s Mounjaro, whose main ingredient is tirzepatide, was approved by the FDA in 2022 to treat diabetes, though it has also been used for weight loss.
☆ How Much It Costs Apple to Make an iPhone 14 Pro Max
  + stars: | 2023-03-23 | by ( Dalvin Brown | ) www.wsj.com   time to read: 1 min
E28How Smartphone Cases Are Ready for New iPhones Even Before They Release As soon as Apple releases new products, third-party cases and compatible accessories seem to instantly hit the shelves. How is this possible when cases can take months to design and mass produce? WSJ’s Dalvin Brown explains. Illustration: Elizabeth Smelov
☆ What Does SVB’s Collapse Mean for the Banking Sector? We'll Explain.
  + stars: | 2023-03-16 | by ( Dion Rabouin | ) www.wsj.com   time to read: 1 min
E50Big Companies Are Planning Record Stock Buybacks. Here’s Why. Companies are on pace to buy back more than $1 trillion worth of their own stock this year. WSJ’s Dion Rabouin explains why companies buy their own stock and why they’re choosing to do so now. Photo: Elizabeth Smelov
☆ How Smartphone Cases Are Ready for New iPhones Even Before They Release
  + stars: | 2023-02-16 | by ( Wall Street Journal | ) www.wsj.com   time to read: 1 min
How Smartphone Cases Are Ready for New iPhones Even Before They Release Here’s what’s going on behind the scenesBy Wall Street Journal Feb 16, 2023 12:00 pm As soon as Apple releases new products, third-party cases and compatible accessories seem to instantly hit the shelves. How is this possible when cases can take months to design and mass produce? WSJ’s Dalvin Brown explains. Illustration: Elizabeth Smelov
☆ Americans Lost $603 Billion by Sticking With Big Banks. Here’s How.
  + stars: | 2023-01-09 | by ( Dion Rabouin | ) www.wsj.com   time to read: 1 min
E43Another Wave of U.S. Layoffs May Be Coming. The layoff announcements just keep coming. As interest rates continue to climb and earnings slump, WSJ’s Dion Rabouin explains why we can expect to see a bigger wave of layoffs in the near future. Illustration: Elizabeth Smelov
☆ Bahrain: The Tiny Island Playing a Big Role in the Middle East
  + stars: | 2023-01-03 | by ( ) www.wsj.com   time to read: 1 min
E28Russia Moves to Annex Four Regions in Ukraine. Here’s Why It Matters. After staging referendums that were widely criticized as a sham, Russia is moving to annex roughly 15% of Ukraine’s territory. WSJ’s Shelby Holliday explains how the process unfolded, and why the attempted land-grab is crucial to Vladimir Putin’s war strategy. Illustration: Elizabeth Smelov
☆ The Yield Curve Is Inverting to Extreme Levels: What Investors Should Know
  + stars: | 2022-12-28 | by ( Dion Rabouin | ) www.wsj.com   time to read: 1 min
E43Another Wave of U.S. Layoffs May Be Coming. The layoff announcements just keep coming. As interest rates continue to climb and earnings slump, WSJ’s Dion Rabouin explains why we can expect to see a bigger wave of layoffs in the near future. Illustration: Elizabeth Smelov
☆ The Yield Curve Has Inverted to Extreme Levels: What Investors Should Know
  + stars: | 2022-12-28 | by ( Dion Rabouin | ) www.wsj.com   time to read: 1 min
E43Another Wave of U.S. Layoffs May Be Coming. The layoff announcements just keep coming. As interest rates continue to climb and earnings slump, WSJ’s Dion Rabouin explains why we can expect to see a bigger wave of layoffs in the near future. Illustration: Elizabeth Smelov
☆ Why the $290 Trillion Global Debt Splurge Is Becoming Unsustainable
  + stars: | 2022-12-20 | by ( Wall Street Journal | ) www.wsj.com   time to read: 1 min
E43Another Wave of U.S. Layoffs May Be Coming. The layoff announcements just keep coming. As interest rates continue to climb and earnings slump, WSJ’s Dion Rabouin explains why we can expect to see a bigger wave of layoffs in the near future. Illustration: Elizabeth Smelov
0 next >>
Total: 25